Comparison Shopping: Guidelines for Statins for Primary Prevention of Cardiovascular Disease
Authors: G.B. John Mancini
Journal: Annals of Internal Medicine (2018)

Editorials16 January 2018Comparison Shopping: Guidelines for Statins for Primary Prevention of Cardiovascular DiseaseG.B. John Mancini, MDG.B. John Mancini, MDUniversity of British Columbia, Vancouver, British Columbia, Canada (G.J.M.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M17-2917 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Developing clinical guidelines is complex. They must be well-focused for intended users and adhere to accepted standards (1, 2). Participants in their development must be selected to balance methodological and clinical expertise while mitigating conflicts of interest. Professional organizations worldwide have access to skilled experts and scientific evidence yet often arrive at different recommendations. These differences reflect the priorities, preferences, local needs, and practical realities of intended users. Thus, guidelines are well-reasoned, sociopolitical statements based on science. I have witnessed the care, professionalism, and passion required to generate a dyslipidemia guideline (3), but consensus can be elusive and, once achieved, ...References1. Laine C, Taichman DB, Mulrow C. Trustworthy clinical guidelines [Editorial]. Ann Intern Med. 2011;154:774-5. [PMID: 21646561]. doi:10.7326/0003-4819-154-11-201106070-00011 LinkGoogle Scholar2. Qaseem A, Forland F, Macbeth F, Ollenschläger G, Phillips S, van der Wees P; Board of Trustees of the Guidelines International Network. Guidelines International Network: toward international standards for clinical practice guidelines. Ann Intern Med. 2012;156:525-31. [PMID: 22473437]. doi:10.7326/0003-4819-156-7-201204030-00009 LinkGoogle Scholar3. Anderson TJ, Grégoire J, Pearson GJ, Barry AR, Couture P, Dawes M, et al. 2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2016;32:1263-1282. [PMID: 27712954] doi:10.1016/j.cjca.2016.07.510 CrossrefMedlineGoogle Scholar4. Mortensen MB, Nordestgaard BG. Comparison of five major guidelines for statin use in primary prevention in a contemporary general population. Ann Intern Med. 2018;168:85-92. doi:10.7326/M17-0681 LinkGoogle Scholar5. Soran H, Schofield JD, Durrington PN. Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment. Eur Heart J. 2015;36:2975-83. [PMID: 26242714] doi:10.1093/eurheartj/ehv340 CrossrefMedlineGoogle Scholar6. Soran H, Schofield JD, Durrington PN. The importance of considering LDL cholesterol response as well as cardiovascular risk in deciding who can benefit from statin therapy. Curr Opin Lipidol. 2014;25:239-46. [PMID: 24978144] doi:10.1097/MOL.0000000000000097 CrossrefMedlineGoogle Scholar7. Mancini GB, Ryomoto A. Comparison of cardiovascular risk assessment algorithms to determine eligibility for statin therapy: implications for practice in Canada. Can J Cardiol. 2014;30:661-6. [PMID: 24882538] doi:10.1016/j.cjca.2014.04.001 CrossrefMedlineGoogle Scholar8. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-207. [PMID: 18997196] doi:10.1056/NEJMoa0807646 CrossrefMedlineGoogle Scholar9. Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L; HOPE-3 Investigators. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374:2021-31. [PMID: 27040132] doi:10.1056/NEJMoa1600176 CrossrefMedlineGoogle Scholar10. Ridker PM, Mora S, Rose L; JUPITER Trial Study Group. Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents. Eur Heart J. 2016;37:1373-9. [PMID: 26916794] doi:10.1093/eurheartj/ehw046 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: University of British Columbia, Vancouver, British Columbia, Canada (G.J.M.)Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M17-2917.Corresponding Author: G.B. John Mancini, MD, University of British Columbia, 2775 Laurel Street, Vancouver, British Columbia V5Z 1M9, Canada; e-mail, [email protected]ubc.ca.This article was published at Annals.org on 2 January 2018. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoComparison of Five Major Guidelines for Statin Use in Primary Prevention in a Contemporary General Population Martin Bødtker Mortensen and Børge Grønne Nordestgaard Metrics Cited byCan We Eliminate Low-Density Lipoprotein Cholesterol-Related Cardiovascular Events Through More Aggressive Primary Prevention Therapy? 16 January 2018Volume 168, Issue 2Page: 145-146KeywordsAlgorithmsAtherosclerosisAtherosclerotic cardiovascular diseaseCardiovascular diseasesDisclosureHeartLow density lipoprotein cholesterolMyocardial infarctionRelative riskStatins ePublished: 2 January 2018 Issue Published: 16 January 2018 Copyright & PermissionsCopyright © 2018 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...